Pharmaceutical Research Associates Group B.V. — Clinical Trial Site

113 Registered trials

21 Currently recruiting

Organisation

Pharmaceutical Research Associates Group B.V.

Location

Groningen, Netherlands

Identifier

ORG-100006268

Address

Van Swietenlaan 6, 9728 NZ, Netherlands

Departments

#001_00270428: Program Management
Clinical research ICON
Clinical Research Unit Groningen
Early Development Service
Early Clinical Services
Early Development
General
N/A
Phase 1 unit
Program Management
Program Management
Program Menagement

Clinical trials at this site (113)

Search interface

A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-06821497 Ended

2023-508371-36-00 small cell lung cancer (SCLC), castration resistant pro 3 2024-07-15
A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and … Ended

2023-503917-31-00 Inflammatory disease 1 2024-06-24
A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C]… Ended

2024-512578-83-00 Not applicable - Healthy volonteers 3 2024-06-24
A randomized, placebo-controlled, double blind, multiple ascending dose, phase 1 study to evaluate the safety, tolerability, and pharmacokin… Ended

2024-513127-16-00 NA - healthy volunteers 3 2024-06-24
A Phase 1, Randomized, Open Label, Single-Dose Crossover Study to Assess the Relative Bioavailability, Food Effect, and Safety of Capsule Fo… Ended

2024-510915-31-00 Not applicable, healthy volunteers 3 2024-06-14
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Ver… Ended

2023-509749-11-00 Healthy volunteers 2 2024-06-05
A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-1… Ended

2023-508279-36-00 Healthy volunteers 3 2024-05-22
A Study to find out the safety, tolerability and interaction of drug with body (including the effect of Itraconazole on RO7268489) and also … Ended

2024-510606-85-00 Not applicable 3 2024-05-10
A SINGLE-CENTER, OPEN-LABEL, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE ITRACONAZOLE, A STRONG CYP3A INHIBITOR, ON THE PHAR… Ended

2024-510732-52-00 Not applicable, healthy volunteers 3 2024-05-07
A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healt… Ended

2023-505026-34-00 Cardiometabolic diseases 1 2024-03-26
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa… Ended

2023-507066-91-00 Infertility 3 2024-03-19
A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-PERIOD, THREE-TREATMENT, BALANCED, SIX-SEQUENCE CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILA… Ended

2023-507661-26-00 Alzheimer’s Disease 3 2024-03-18
Study to Assess the Effect of Food on the Pharmacokinetics of CA-4948 in Healthy Male Subjects Ended

2023-509691-41-00 Hematologic malignancies 3 2024-03-14
A PHASE I, OPEN-LABEL, RANDOMIZED, ADAPTIVE, CROSS-OVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF NIZUBAGLUSTAT CAPSULES COMPARED T… Ended

2023-510058-17-00 Glycosphingolipid lysosomal storage disorders 3 2024-03-12
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by t… Ended

2023-508030-33-00 Healthy volunteers 8 2024-03-01
A study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Ph… Ended

2023-508382-33-01 Proteinopathies 3 2024-02-22
A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEAL… Ended

2023-509086-20-00 Cardiac arrhythmias 3 2024-02-13
A RANDOMIZED, DOUBLE-BLIND, THREE-PART, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSS-OVER STUDY TO COMPARE THE PHARMACOKINETICS (PK), SAFETY… Ended

2023-507877-17-00 Not applicable, Healthy Volunteers 2 2024-02-12
ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults. Ended

2023-507074-40-00 metastatic/advanced breast cancer 3 2024-01-26
A study to learn how BAY2927088 is taken up and handled by the body in healthy male participants Ended

2022-502771-38-00 Advanced non-small cell lung cancer with EGFR and/or HE 3 2024-01-24
A study to investigate the mass balance, absolute bioavailability (BA), pharmacokinetics (PK), and metabolism of a single oral dose 60 mg [1… Ended

2023-506044-16-00 There is no medical condition being investigated. 3 2023-12-14
A study in healthy men to test how BI 1291583 is taken up by the body Ended

2023-505683-11-00 Healthy volunteer trial 3 2023-12-12
A study to investigate the pharmacokinetics of remibrutinib in CSF in healthy participants. Ended

2023-506760-13-00 Healthy 3 2023-12-11
A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess th… Ended

2023-505542-26-00 Heart failure (HF) 1 2023-11-30